ATI commences European trial of neurostimulation program for migraine Autonomic Technologies.

ATI commences European trial of neurostimulation program for migraine Autonomic Technologies, Inc . , the programmer of a novel miniaturized implantable stimulator for serious headaches, today announced initiation of a study in Europe to evaluate the safety and efficacy of the business’s investigational neurostimulation program for the treating high rate of recurrence, high disability migraine. The multi-center, randomized Pathway M-1 study will enroll 30 sufferers initially at leading headache centers in Denmark, Belgium, Spain, Germany and France. Migraine is the many common disabling headache, influencing 11 percent of the population in Western European countries and america. It really is marked by pulsating, moderate to serious pain lasting from 4-72 hours, and could be connected with nausea and sensitivity to light or sound.

The award will be presented through the ATA 2012 Meeting and Exposition, April 28 to May 1, in San Jose, Ca. Winners of the annual awards have got demonstrated ‘a long-term commitment to expanding the quality and accessibility of health care through telemedicine and mobile healthcare applications,’ stated ATA president Dr. Bernard Harris, Jr. ‘Their work has preserved and improved countless lives.’ Related StoriesResearch with UWF imaging may switch how diabetic eyes disease can be assessed and treatedApplying a high restaurant model to health care communications: an interview with Brandi Robinson, SanofiThe Iowa Clinic selects TCS' VirtuMedix system to supply secure telemedicine providers to family medicine patientsThe Pediatric Telehealth SIG offers advanced ATA’s objective by marketing pediatric telemedicine through exterior collaboration and outreach and by developing educational possibilities for ATA members and nonmembers.